EFFECTS OF LACIDIPINE AND EXTENDED RELEASE NIFEDIPINE IN PATIENTS WITH HYPERTENSION
0
Citation
0
Reference
20
Related Paper
Abstract:
[Objective] To evaluate the effects of the lacidipine combined extended release nifedipine on hypertensive patients.[Methods]158 cases of hypertensive patients were collected in our hospital,and were divided into extended release nifedipine group,lacidipine and extended release nifedipine group.The duration of treatment was 6 months.Diastolic blood pressure(DBP),systolic blood pressure(SBP),heart rate(HR),intima-media thickness of the common carotid artery(IMTcca),IMT of the bifurcating coronary artery(IMTbif),IMT of the internal carotid artery(IMTica),left ventricular spetum thickness(LVST),left ventricular end-diastolic posterior wall thickness(LVPWT),LV internal diameter (LVID),left ventricular mass index(LVMI),flow-mediated brachial artery dilation(FMD),high-sensitivity C-reactive protein(hs-CRP)were observed in all patients.[Results]Six months medical treatment revealed that SBP of lacidipine and extended release nifedipine group was significantly diminished from 159.4 mmHg to 127.1 mmHg,and that of Extended Release Nifedipine group was down from 99.7 mmHg to 78.4mmHg(P﹤0.05).The levels of IMTs of the lacidipine and extended release nifedipine group were significantly lower.However,whereas the IMTs of Extended Release Nifedipine group did not show any significant changes(P﹥0.05).Compared with extended release nifedipine group,the hs-CRP was also lower.Lacidipine and extended release nifedipine group significantly improved the condition of heart.[Conclusion]lacidipine and extended release nifedipine group leads to a significant reduction of BP of patients with hypertension as well as to a decrease in markers of inflammation during a relatively short period(6 months).Keywords:
Lacidipine
Brachial artery
Cite
To elucidate the mechanisms of action of nifedipine in angina pectoris, 14 patients were studied before and after sublingual administration of 10 mg nifedipine. Systemic and coronary hemodynamic and myocardial metabolic measurements were taken at rest and during pacing. At the pacing rate that induced pain in the control situation, no patient experienced angina after nifedipine administration. Lactate production during control turned into extraction after nifedipine administration (p less than .05), and the double product was reduced (p less than .001). Systemic and coronary vascular resistance were reduced by 26% (p less than .001) and 19% (p less than .005), respectively. Systolic blood pressure fell from 160 +/- 29 to 127 +/- 25 mm Hg (p less than .001) and diastolic from 100 +/- 14 to 79 +/- 11 mm Hg (p less than .001). Pulmonary artery diastolic blood pressure fell from 14 +/- 4 to 10 +/- 3 mm Hg (p less than .01). When the pacing rate was further increased after nifedipine administration until pain ...
Sublingual administration
Cite
Citations (0)
The comparative efficacy of the calcium antagonists isradipine and nifedipine in reducing left ventricular peak systolic wall tension was assessed in 25 patients with essential hypertension (20 men, 5 women; mean age: 49 years). After 2 weeks of treatment with either isradipine (2.5 mg twice daily) or slow-release nifedipine (20 mg twice daily), blood pressure was similarly reduced in both groups of patients whereas the thickness of the interventricular septum and left ventricular free wall did not change. Echocardiographic end-diastolic volume of the left ventricle showed no change whereas end-systolic volume significantly decreased with isradipine, but not with nifedipine retard. This led to a significant reduction in peak systolic wall tension in the isradipine group, but not in the nifedipine group. In conclusion, antihypertensive treatment with isradipine produces a reduction in peak systolic wall tension which is not seen with nifedipine, probably because of its negative inotropic effect. Am J Hypertens 1993;6:92S-94S
Isradipine
Interventricular septum
Cite
Citations (1)
Nifedipine is a Ca-antagonist drug that reduces contractility of vascular smooth muscle, and is used in the treatment of arterial hypertension and of stable and vasospastic angina. Aim of this study is to evaluate long-term effect of nifedipine on distribution of body fluid compartment, assessed by BIA (Bio-Impedance Analysis), and on cardiac function, in hypertensive patients on dialysis. Two groups of hypertensive patients were compared: a) a first group of nine patients (5 Male, 4 Female; age 62.67 +/- 10.39) treated with nifedipine (30 mg/day) for one year; b) a control group of sixteen dialysis patients (9 Male, 7 Female; age 56.31 +/- 14.44), previously hypertensive, with normal blood pressure without anti-hypertensive drugs for three months or more. By BIA, extracellular water percentage (ECW%) is higher in nifedipine-treated patients (p < 0.001) in comparison with the control group before dialysis; no other difference is present. The intradialytical variations (before dialysis vs. the end of dialysis) of body fluid compartments are a significant decrease of total body water % (52.33 +/- 2.89 vs. 48.72 +/- 3.35, p < 0.001), ECW% (40.97 +/- 2.2 vs. 37.56 +/- 3.47, p < 0.005), Left Ventricular End-Diastolic Volume (81.1 +/- 14.6 vs. 63.4 +/- 21.66 ml/m2, p < 0.003), Cardiac Output (3.35 +/- 0.71 vs. 2.51 +/- 0.76 l/min/m2, p < 0.04) and Stroke Volume (45.76 +/- 10.21 vs. 34.34 +/- 9.98 ml/m2, p < 0.02) in nifedipine-treated patients. Our findings suggest that nifedipine induces intermittent and prolonged expansion of extra-cellular volume. This condition, in patients otherwise without clinical and echocardiographic signs of heart failure, can be potentially detrimental for cardiac function on long-term nifedipine treatment.
Contractility
Cite
Citations (1)
Objective To ivvestigate the clinical effect of Atorvastatin calcium combined with Extended Release Nifedipine Tablets in the treatment of mild to moderate hypertension complicated with heart disease its effect on liver and renal function. Methods 150 patients with mild to moderate hypertension and left ventricular hypertrophy were divided into two groups,the control group was given Extended Release Nifedipine Tablets,the treatment was given atorvastatin calcium in addition to Extended Release Nifedipine Tablets.After 18 months of treatment,The blood pressure,left ventricular posterior wall thickness(LVPW),ventricular septal thickness(IVS)and the function of liver and kidney were compared between the two groups. Results The blood pressure of the 2 groups after treatment were standard.The systolic pressure,diastolic pressure decreased more significantly in the observation group than the control group.The LVPW and IVS were improved more obviously in the observation group.2 patients in the observation group appeared elevated transaminase and then reduced after the discontinuation of atorvastatin calcium.1 case in the control group appeared liver and kidney function damage. Conclusion Atorvastatin calcium combined with extended release nifedipine tablets has good effect in the treatment of mild to moderate hypertension with left ventricular hypertrophy,and has no obvious damage of liver and kidney.
Transaminase
Cite
Citations (0)
Tolerability
Brain natriuretic peptide
Cite
Citations (2)
Both nifedipine and captopril are effective in the treatment of systemic hypertension in the elderly, but their effects on cardiac function in this age group have not been evaluated. We studied the effects of acute oral administration of 20 mg nifedipine and 12.5 mg captopril on systolic and diastolic cardiac function, as evaluated by a radionuclide method, in 14 elderly hypertensives, mean age 73.4 +/- 3.9 years. The radionuclide studies were performed 1 h after ingestion of nifedipine and 1.5 h after captopril, on separate days. Nifedipine accelerated the heart rate whereas captopril slowed it. Nifedipine increased the ejection fraction by 2.6 +/- 14.6% but captopril increased it by 13 +/- 15.3%. Nifedipine reduced the left ventricular peak ejection rate by 4.8 +/- 21.7% whereas captopril increased it by 18 +/- 24.3%. Nifedipine increased the peak filling rate by 14.3 +/- 41.6% and captopril increased it by 27.6 +/- 32.6%. Nifedipine reduced the time to peak filling rate by 24.9 +/- 27.0%, but captopril reduced it by 68.8 +/- 59.6%. All these differences were statistically significant. Therefore, captopril improves some diastolic and systolic parameters of cardiac function more than nifedipine does. Other parameters are impaired by nifedipine but improved by captopril.
Captopril
Cite
Citations (4)
Felodipine
Atenolol
Systole
Cite
Citations (4)
Objective To explore the effect of irbesartan combined with nifedipine controlled release tablet in the treatment of hypertension. Methods 80 cases of patients with hypertension were selected and randomly divided into two groups.In observation group,patients were treated by irbesartan combined with nifedipine controlled release tablet,while in control group,metoprolol combined with nifedipine controlled release tablet were provided.The renal function,mean arterial pressure and change of ultrasonic cardiogram after treatment in two groups was compared respectively. Results After therapy,the levels of urea nitrogen and creatinine,mean arterial pressure in the observation group was greatly lower than that in the control group respectively,with statistical difference(P0.05).The interventricular septal thickness and left ventricular end diastolic diameter in the observation group after treatment was remarkably less than that in the control group respectively,with statistical difference(P0.05).The left ventricular ejection fraction in the observation group was higher than that in the control group,with statistical difference(P 0.05). Conclusion Irbesartan combined with nifedipine controlled release tablet play a more obvious reverse effect on left ventricle hypertrophy in hypertension patient,better control patient′s blood pressure and protect renal function simultaneously.
Irbesartan
Cite
Citations (0)
We conducted a randomly allocated, double-blind study in 16 essential hypertensive patients, eight of whom were treated with nifedipine and eight with lacidipine. The antihypertensive efficacy was evaluated and any modifications to peripheral haemodynamic parameters were observed in the brachial artery by a mechanographic method and B-mode scanner with a 10-MHz probe. Statistically significant reductions In blood pressure from basal values were observed after 1 and 6 months' treatment. Enhanced compliance (P < 0.005), reduced characteristic impedance (P < 0.001) and lower peripheral resistances (P < 0.01) were also noted. Variations In pulse wave velocity and mean blood pressure showed a statistically significant correlation as early as the first month of treatment (P < 0.01 ). Our results suggest that therapy with nifedipine and lacidlpine allows an improvement in peripheral haemodynamics in hypertensive patients. This response is maintained in chronic treatment, even just before the next dose administration at the end of the longest dose interval.
Lacidipine
Brachial artery
Basal (medicine)
Cite
Citations (13)
Abstract In an open randomized study, hemodynamic and antianginal effects of nifedipine and the new dihydropyridine derivative isradipine were compared in patients with stable, angiographically confirmed coronary heart disease. Right heart hemodynamics, systemic arterial blood pressure, ECG, and drug plasma concentrations were measured before medication at rest and exercise, after infusions of increasing doses at rest, and again after treatment at rest and exercise. A linear relationship between serum concentrations and cumulated dosages was obtained for both drugs. At rest, both drugs significantly increased cardiac output and heart rate. The reduction of arterial blood pressure was significantly greater after isradipine (systolic from 148±3 to 104±3 mmHg; diastolic from 90±4 to 58±2 mmHg) than after nifedipine (systolic 149±6 to 125±4 mmHg; diastolic 92±4 to 76±3 mmHg). The minimal effective plasma level of isradipine regarding blood pressure reduction was estimated at 5 ng/ml (nifedipine: 10–25 ng/ml). During exercise both medications significantly reduced mean pulmonary artery pressure (isradipine: 40±3 to 20±1 mmHg, nifedipine: 37±4 to 22±1 mmHg), pulmonary artery wedge pressure (isradipine: 23±3 to 10±1 mmHg, nifedipine 24±3 to 14±1 mmHg), and diastolic arterial pressure (isradipine: 103±3 to 73±4 mmHg, nifedipine: 99±3 to 91±2 mmHg), whereas systolic pressure was reduced by only isradipine (189±4 to 147±5 mmHg). Neither medication significantly changed electrocardiographic ST depression during exercise. There was a high rate of painless ST depression (nifedipine 1/8, isradipine 4/8) during the drug dosing and increased ST depression during exercise. This phenomenon can be explained by either coronary steal or by ST depression of unknown origin after dihydropyridine treatment.
Isradipine
Pulmonary wedge pressure
Cite
Citations (3)